ribociclib
novartis
['ribociclib']
#asco2022 kalinsky maintain randomized phase 2 trial, in which patients progressing on ai + cdk 4/6 randomized to exemestane or. fulvestrant vs exemestane or fulvestrant plus ribociclib. pfs primary endpoint. pfs of 2.7 vs 5.2 mo, statistically significant. most pts got fulvest.
Professor of Medicine, Stanford University; breast cancer doc